37 RESULTS
COMMENT PET measurements of presynaptic and postsynaptic density would greatly advance the scientific study of Alzheimer’s disease and related disorders. The Yale group has developed this promising 11 C-labeled ligand to assess presynaptic density. They have begu
COMMENT I was disappointed to learn this news, but the findings are not entirely surprising. Merck’s BACE inhibitor verubecestat demonstrated no significant effects in clinically affected patients, and we have long suspected that this particular drug class might
COMMENT It is encouraging to learn of this BACE inhibitor’s promising preliminary findings, including the possibility of treatment-related difference in PET measurements of amyloid plaque deposition, initial evidence of the drug’s safety and tolerability, and the
COMMENT While last week’s announcement is disappointing, we believe that BACE inhibitors still hold promise in stopping the accumulation of amyloid and preventing the clinical onset of Alzheimer’s disease—particularly in healthy people who are at increased risk o
COMMENT In 2011, a task force for NIA and the Alzheimer’s Association conceptualized Alzheimer’s disease as a progressive sequence of pathophysiological changes which correspond roughly to preclinical (“cognitively unimpaired”), MCI, and dementia stages. The 2018
COMMENT Like others in the field, I was disappointed to read about the external data monitoring committee’s (eDMC’s) finding that the BACE inhibitor verubecestat was unlikely to demonstrate “a positive benefit/risk” if the APECS study was completed in persons wit
COMMENT In this meta-analysis of data from nearly 58,000 cases and controls, the authors report no overall sex differences in clinical AD risk in ApoE4 heterozygotes or homozygotes 55–85 years of age. But they did see higher odds ratios in women at younger ages (
COMMENT I am a big fan of the work Marc Raichle and his colleagues have done relating to both the default mode network and aerobic glycolysis. It is an understudied process that may be of great importance to brain development, brain aging, and the predisposition
COMMENT This interesting study found an association between the difficulty of a visuospatial judgment task and deactivation of the precuneus and other regions in the default mode network, a preferential relationship between age and less task-dependent DMN deactiv
COMMENT Allen was a founding adviser to the Arizona Alzheimer’s Disease Core Center and Alzheimer’s Consortium. He was a pioneer in Alzheimer's and neuromuscular disease research, genetics, and related fields. It was his laboratory's discovery of APOE4,
COMMENT Dale was a true pioneer in Alzheimer’s research. As head of R&D at Elan, he and his colleagues introduced the first transgenic mouse model of AD, the first amyloid vaccine and passive immunotherapy for Alzheimer’s, and other groundbreaking approaches
COMMENT Kunz and colleagues report that entorhinal grid-cell function in young adult APOE e4 carriers is deficient relative to non-carriers. To put this in perspective, some background may be helpful. The close correlation between neuronal activity and spatial na
COMMENT We thank Dr. Chetelat for her kind remarks and thoughtful input. While there are some differences between the DIAN and API data, we continue to be impressed by the consistency of our findings, especially given the relatively small sample sizes, large conf
COMMENT In this elegant study, Beth Mormino, Reisa Sperling, and their colleagues support the hypothesis that biomarker measurements of fibrillar amyloid deposition in cognitively unimpaired older adults are associated with an indicator of subsequent cognitive de
COMMENT This elegant and important study finds an association between a rare APP variant and a lower risk of AD, and it provides strong evidence to suggest that the protective effects of this variant may be attributable to reductions in BACE1-mediated APP cleavag
